Abstract
Introduction: Targeting ubiquitin-proteasome system (UPS) has emerged as a rational approach in the treatment of human cancer. The therapeutic potential of this pathway has been validated by the clinical successes of bortezomib – the first proteasome inhibitor drug implemented in the therapy of multiple myeloma and mantle cell lymphoma. However, the treatment of solid tumors remains challenging, mostly due to poor tumor-selective drug delivery and low therapeutic efficacy. Previously, we reported on the development of novel potential therapeutic – CPL-410-005 – a non-selective, cell permeable, inhibitor of ubiquitin-activating enzyme (E1).
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
